Preclinical safety and efficacy of an anti-HIV-1 lentiviral vector containing a short hairpin RNA to CCR5 and the C46 fusion inhibitor

Molecular Therapy Methods and Clinical Development

Volumn 1, Issue , 2014, Pages 11-

  Wolstein, Orit ^a   Boyd, Maureen ^a   Millington, Michelle ^a   Impey, Helen ^a   Boyer, Joshua ^b   Howe, Annett ^a   Delebecque, Frederic ^a   Cornetta, Kenneth ^c   Rothe, Michael ^d   Baum, Christopher ^d   Nicolson, Tamara ^a   Koldej, Rachel ^a   Zhang, Jane ^a   Keech, Naomi ^a   Camba Colón, Joanna ^a   Breton, Louis ^a   Bartlett, Jeffrey ^a   An, Dong Sung ^b,c,e   Chen, Irvin Sy ^b,e   Burke, Bryan ^a   Symonds, Geoff P ^a   more..

^a Calimmune Australia Inc   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84938412743     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2013.11     Document Type: Article

References (81)

1. Günthard, HF, Frost, SD, Leigh-Brown, AJ, Ignacio, CC, Kee, K, Perelson, AS et al. (1999). Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol 73: 9404-9412.
2. Persaud, D, Siberry, GK, Ahonkhai, A, Kajdas, J, Monie, D, Hutton, N et al. (2004). Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol 78: 968-979.
3. Ruff, CT, Ray, SC, Kwon, P, Zinn, R, Pendleton, A, Hutton, N et al. (2002). Persistence of wild-type virus and lack of temporal structure in the latent reservoir for human immunodeficiency virus type 1 in pediatric patients with extensive antiretroviral exposure. J Virol 76: 9481-9492.
4. Chun, TW, Davey, RT Jr, Engel, D, Lane, HC and Fauci, AS (1999). Re-emergence of HIV after stopping therapy. Nature 401: 874-875.
5. Davey, RT Jr, Bhat, N, Yoder, C, Chun, TW, Metcalf, JA, Dewar, R et al. (1999). HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA 96: 15109-15114.
6. Harrigan, PR, Whaley, M and Montaner, JS (1999). Rate of HIV-1 RNA rebound upon stopping antiretroviral therapy. AIDS 13: F59-F62.
7. Nolan, D, Reiss, P and Mallal, S (2005). Adverse effects of antiretroviral therapy for HIV infection: a review of selected topics. Expert Opin Drug Saf 4: 201-218.
8. Shafer, RW and Schapiro, JM (2008). HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 10: 67-84.
9. Reust, CE (2011). Common adverse effects of antiretroviral therapy for HIV disease. Am Fam Physician 83: 1443-1451.
10. Thompson, MA, Aberg, JA, Hoy, JF, Telenti, A, Benson, C, Cahn, P et al. (2012). Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 308: 387-402.
11. Mitsuyasu, RT, Zack, JA, Macpherson, JL and Symonds, GP (2011). Phase I/II clinical trials using gene-modified adult hematopoietic stem cells for HIV: lessons learnt. Stem Cells Int 2011: 393698.
12. Rossi, JJ, June, CH and Kohn, DB (2007). Genetic therapies against HIV. Nat Biotechnol 25: 1444-1454.
13. Symonds, G P, Johnstone, HA, Millington, ML, Boyd, MP, Burke, BP and Breton, LR (2010). The use of cell-delivered gene therapy for the treatment of HIV/AIDS. Immunol Res 48: 84-98.
14. Chung, J, Rossi, JJ and Jung, U (2011). Current progress and challenges in HIV gene therapy. Future Virol 6: 1319-1328.
15. Dean, M, Carrington, M, Winkler, C, Huttley, GA, Smith, MW, Allikmets, R et al. (1996). Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273: 1856-1862.
16. Dragic, T, Litwin, V, Allaway, G P, Martin, SR, Huang, Y, Nagashima, KA et al. (1996). HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381: 667-673.
17. Liu, R, Paxton, WA, Choe, S, Ceradini, D, Martin, SR, Horuk, R et al. (1996). Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86: 367-377.
18. Samson, M, Libert, F, Doranz, BJ, Rucker, J, Liesnard, C, Farber, CM et al. (1996). Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382: 722-725.
19. Ioannidis, JP, Rosenberg, PS, Goedert, JJ, Ashton, LJ, Benfield, TL, Buchbinder, SP et al.; International Meta-Analysis of HIV Host Genetics. (2001). Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 135: 782-795.
20. O'Brien, SJ and Nelson, GW (2004). Human genes that limit AIDS. Nat Genet 36: 565-574.
21. Huang, Y, Paxton, WA, Wolinsky, SM, Neumann, AU, Zhang, L, He, T et al. (1996). The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med 2: 1240-1243.
22. Glass, WG, McDermott, DH, Lim, JK, Lekhong, S, Yu, SF, Frank, WA et al. (2006). CCR5 deficiency increases risk of symptomatic West Nile virus infection. J Exp Med 203: 35-40.
23. Hütter, G, Nowak, D, Mossner, M, Ganepola, S, Müssig, A, Allers, K et al. (2009). Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360: 692-698.
24. Allers, K, Hütter, G, Hofmann, J, Loddenkemper, C, Rieger, K, Thiel, E et al. (2011). Evidence for the cure of HIV infection by CCR5?32/?32 stem cell transplantation. Blood 117: 2791-2799.
25. Feng, Y, Leavitt, M, Tritz, R, Duarte, E, Kang, D, Mamounas, M et al. (2000). Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5. Virology 276: 271-278.
26. DiGiusto, DL, Krishnan, A, Li, L, Li, H, Li, S, Rao, A et al. (2010). RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci Transl Med 2: 36ra43.
27. Cordelier, P, Kulkowsky, JW, Ko, C, Matskevitch, AA, McKee, HJ, Rossi, JJ et al. (2004). Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5. Gene Ther 11: 1627-1637.
28. Bai, J, Gorantla, S, Banda, N, Cagnon, L, Rossi, J and Akkina, R (2000). Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol Ther 1: 244-254.
29. Steinberger, P, Andris-Widhopf, J, Bühler, B, Torbett, BE and Barbas, CF 3rd (2000). Functional deletion of the CCR5 receptor by intracellular immunization produces cells that are refractory to CCR5-dependent HIV-1 infection and cell fusion. Proc Natl Acad Sci USA 97: 805-810.
30. Anderson, J, Banerjea, A and Akkina, R (2003). Bispecific short hairpin siRNA constructs targeted to CD4, CXCR4, and CCR5 confer HIV-1 resistance. Oligonucleotides 13: 303-312.
31. Qin, XF, An, DS, Chen, IS and Baltimore, D (2003). Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc Natl Acad Sci USA 100: 183-188.
32. Anderson, J and Akkina, R (2005). HIV-1 resistance conferred by siRNA cosuppression of CXCR4 and CCR5 coreceptors by a bispecific lentiviral vector. AIDS Res Ther 2: 1.
33. Anderson, JS, Javien, J, Nolta, JA and Bauer, G (2009). Preintegration HIV-1 inhibition by a combination lentiviral vector containing a chimeric TRIM5 alpha protein, a CCR5 shRNA, and a TAR decoy. Mol Ther 17: 2103-2114.
34. Butticaz, C, Ciuffi, A, Muñoz, M, Thomas, J, Bridge, A, Pebernard, S et al. (2003). Protection from HIV-1 infection of primary CD4 T cells by CCR5 silencing is effective for the full spectrum of CCR5 expression. Antivir Ther (Lond) 8: 373-377.
35. Kim, SS, Peer, D, Kumar, P, Subramanya, S, Wu, H, Asthana, D et al. (2010). RNAi-mediated CCR5 silencing by LFA-1-targeted nanoparticles prevents HIV infection in BLT mice. Mol Ther 18: 370-376.
36. Shimizu, S, Hong, P, Arumugam, B, Pokomo, L, Boyer, J, Koizumi, N et al. (2010). A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 115: 1534-1544.
37. Liang, M, Kamata, M, Chen, KN, Pariente, N, An, DS and Chen, IS (2010). Inhibition of HIV-1 infection by a unique short hairpin RNA to chemokine receptor 5 delivered into macrophages through hematopoietic progenitor cell transduc tion. J Gene Med 12: 255-265.
38. Perez, EE, Wang, J, Miller, JC, Jouvenot, Y, Kim, KA, Liu, O et al. (2008). Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat Biotechnol 26: 808-816.
39. Holt, N, Wang, J, Kim, K, Friedman, G, Wang, X, Taupin, V et al. (2010). Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 28: 839-847.
40. Briefs, B (2009). Trial watch: novel HIV gene therapy enters Phase I trial. Nat Rev Drug Disc 8: 267.
41. An, DS, Donahue, RE, Kamata, M, Poon, B, Metzger, M, Mao, SH et al. (2007). Stable reduction of CCR5 by RNAi through hematopoietic stem cell transplant in non-human primates. Proc Natl Acad Sci USA 104: 13110-13115.
42. Shimizu, S, Kamata, M, Kittipongdaja, P, Chen, KN, Kim, S, Pang, S et al. (2009). Characterization of a potent non-cytotoxic shRNA directed to the HIV-1 co-receptor CCR5. Genet Vaccines Ther 7: 8.
43. Egelhofer, M, Brandenburg, G, Martinius, H, Schult-Dietrich, P, Melikyan, G, Kunert, R et al. (2004). Inhibition of human immunodeficiency virus type 1 entry in cells expressing gp41-derived peptides. J Virol 78: 568-575.
44. Hildinger, M, Dittmar, MT, Schult-Dietrich, P, Fehse, B, Schnierle, BS, Thaler, S et al. (2001). Membrane-anchored peptide inhibits human immunodeficiency virus entry. J Virol 75: 3038-3042.
45. Lohrengel, S, Hermann, F, Hagmann, I, Oberwinkler, H, Scrivano, L, Hoffmann, C et al. (2005). Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides. J Virol 79: 10237-10246.
46. Zahn, RC, Hermann, FG, Kim, EY, Rett, MD, Wolinsky, SM, Johnson, RP et al. (2008). Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides. Gene Ther 15: 1210-1222.
47. van Lunzen, J, Glaunsinger, T, Stahmer, I, von Baehr, V, Baum, C, Schilz, A et al. (2007). Transfer of autologous gene-modified T cells in HIV-infected patients with advanced immunodeficiency and drug-resistant virus. Mol Ther 15: 1024-1033.
48. Chen, TK and Aldrovandi, GM (2008). Review of HIV antiretroviral drug resistance. Pediatr Infect Dis J 27: 749-752.
49. Cane, PA (2009). New developments in HIV drug resistance. J Antimicrob Chemother 64 (suppl. 1): i37-i40.
50. Buchacz, K, Baker, R, Ward, DJ, Palella, FJ, Chmiel, JS, Young, B et al. (2012). Trends in decline of antiretroviral resistance among ARV-experienced patients in the HIV outpatient study: 1999-2008. AIDS Res Treat 2012: 230290.
51. Doranz, BJ, Rucker, J, Yi, Y, Smyth, RJ, Samson, M, Peiper, SC et al. (1996). A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85: 1149-1158.
52. Endres, MJ, Clapham, PR, Marsh, M, Ahuja, M, Turner, JD, McKnight, A et al. (1996). CD4-independent infection by HIV-2 is mediated by fusin/CXCR4. Cell 87: 745-756.
53. Feng, Y, Broder, CC, Kennedy, PE and Berger, EA (1996). HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 272: 872-877.
54. Langford, SE, Ananworanich, J and Cooper, DA (2007). Predictors of disease progression in HIV infection: a review. AIDS Res Ther 4: 11.
55. Ray, N and Doms, RW (2006). HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol 303: 97-120.
56. Regoes, RR and Bonhoeffer, S (2005). The HIV coreceptor switch: a population dynamical perspective. Trends Microbiol 13: 269-277.
57. Tsibris, AM and Kuritzkes, DR (2007). Chemokine antagonists as therapeutics: focus on HIV-1. Annu Rev Med 58: 445-459.
58. Nenoi, M, Mita, K, Ichimura, S, Cartwright, IL, Takahashi, E, Yamauchi, M et al. (1996). Heterogeneous structure of the polyubiquitin gene UbC of HeLa S3 cells. Gene 175: 179-185.
59. Bianchi, M, Crinelli, R, Giacomini, E, Carloni, E and Magnani, M (2009). A potent enhancer element in the 5'-UTR intron is crucial for transcriptional regulation of the human ubiquitin C gene. Gene 448: 88-101.
60. Modlich, U, Navarro, S, Zychlinski, D, Maetzig, T, Knoess, S, Brugman, MH et al. (2009). Insertional transformation of hematopoietic cells by self-inactivating lentiviral and gammaretroviral vectors. Mol Ther 17: 1919-1928.
61. Cornetta, K, Yao, J, Jasti, A, Koop, S, Douglas, M, Hsu, D et al. (2011). Replication-competent lentivirus analysis of clinical grade vector products. Mol Ther 19: 557-566.
62. Scholler, J, Brady, TL, Binder-Scholl, G, Hwang, WT, Plesa, G, Hege, KM et al. (2012). Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med 4: 132ra53.
63. Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F et al. (2010). Transfusion independence and HMGA2 activation after gene therapy of human ß-thalassaemia. Nature 467: 318-322.
64. Cartier, N, Hacein-Bey-Abina, S, Bartholomae, CC, Veres, G, Schmidt, M, Kutschera, I et al. (2009). Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326: 818-823.
65. Seymour, LW and Thrasher, AJ (2012). Gene therapy matures in the clinic. Nat Biotechnol 30: 588-593.
66. Murray, JM, Fanning, GC, Macpherson, JL, Evans, LA, Pond, SM and Symonds, GP (2009). Mathematical modelling of the impact of haematopoietic stem cell-delivered gene therapy for HIV. J Gene Med 11: 1077-1086.
67. Younan, PM, Polacino, P, Kowalski, J P, Peterson, CW, Maurice, NJ, Williams, NP et al. (2013). Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. Blood 122: 179-187.
68. Kitchen, SG, Shimizu, S and An, DS (2011). Stem cell-based anti-HIV gene therapy. Virology 411: 260-272.
69. von Laer, D, Hasselmann, S and Hasselmann, K (2006). Gene therapy for HIV infection: what does it need to make it work? J Gene Med 8: 658-667.
70. Applegate, TL, Birkett, DJ, Mcintyre, GJ, Jaramillo, AB, Symonds, G and Murray, JM (2010). In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy. Retrovirology 7: 83.
71. Aviran, S, Shah, PS, Schaffer, DV and Arkin, AP (2010). Computational models of HIV-1 resistance to gene therapy elucidate therapy design principles. PLoS Comput Biol 6: e1000883.
72. Lund, O, Lund, OS, Gram, G, Nielsen, SD, Schønning, K, Nielsen, JO et al. (1997). Gene therapy of T helper cells in HIV infection: mathematical model of the criteria for clinical effect. Bull Math Biol 59: 725-745.
73. Schuitemaker, H, Koot, M, Kootstra, NA, Dercksen, MW, de Goede, RE, van Steenwijk, RP et al. (1992). Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 66: 1354-1360.
74. Keele, BF, Giorgi, EE, Salazar-Gonzalez, JF, Decker, JM, Pham, KT, Salazar, MG et al. (2008). Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 105: 7552-7557.
75. Cannon, P and June, C (2011). Chemokine receptor 5 knockout strategies. Curr Opin HIV AIDS 6: 74-79.
76. Barton, KM, Burch, BD, Soriano-Sarabia, N and Margolis, DM (2013). Prospects for treatment of latent HIV. Clin Pharmacol Ther 93: 46-56.
77. Connor, RI, Sheridan, KE, Ceradini, D, Choe, S and Landau, NR (1997). Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185: 621-628.
78. Kimpel, J, Braun, SE, Qiu, G, Wong, FE, Conolle, M, Schmitz, JE et al. (2010). Survival of the fittest: positive selection of CD4+ T cells expressing a membrane-bound fusion inhibitor following HIV-1 infection. PLoS ONE 5: e12357.
79. Peterson, CW, Younan, P, Jerome, KR and Kiem, HP (2013). Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART. Gene Ther 20: 695-702.
80. Mangeot, PE, Duperrier, K, Nègre, D, Boson, B, Rigal, D and Cosset, FL et al. (2002). High levels of transduction of human dendritic cells with optimized SIV vectors. Mol Ther 5: 283-290.
81. Leath, A and Cornetta, K (2012). Developing novel lentiviral vectors into clinical products. Meth Enzymol 507: 89-108.